A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma

Cancer

Volumn 78, Issue 3 SUPPL., 1996, Pages 627-632

  Rothenberg, Mace L ^a,g   Abbruzzese, James L ^b   Moore, Malcolm ^c   Portenoy, Russell K ^d   Robertson, John M ^e   Wanebo, Harold J ^f  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c PRINCESS MARGARET HOSPITAL   (Canada)

^d MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f BROWN UNIVERSITY   (United States)

^g NONE   (United States)

Author keywords

clinical benefit; clinical trial design; pain; pancreatic carcinoma; performance status; quality of life

Indexed keywords

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; HUMAN; PANCREAS CARCINOMA; PERFORMANCE; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME;

CLINICAL TRIALS; HUMANS; PANCREATIC NEOPLASMS;

EID: 0029973785     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960801)78:3<627::AID-CNCR43>3.0.CO;2-Y     Document Type: Article

References (48)

1. Asbury RF, Cnaan A, Johnson L, Harris J, Zaentz SD, Haller DG. An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, aclacinomycin, or spirogermanium in metastatic pancreatic cancer. Am J Clin Oncol 1994;17:166-9.
2. Linke K, Pazdur R, Abbruzzese JL, Ajan JA, Winn R, Bradof JR, et al. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs 1991;9:353-6.
3. Leichman CG, Tangen C, Macdonald JS, Leimert T, Fleming TR. Phase II trial of amonafide in advanced pancreas cancer: a Southwest Oncology Group trial. Invest New Drugs 1993;11:219-21.
4. Bukowski RM, Fleming TR, Macdonald JS, Oishi N, Taylor SA, Baker. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma: a Southwest Oncology Group study. Cancer 1993;71:322-5.
5. Moore M, Maroun J, Robert F, Natale R, Neidhart J, Daillaire B, et al. Multicenter phase H study of brequinar sodium in patients with advanced gastrointestinal cancer. Invest New Drugs 1993;11:61-5.
6. Kajanti MJ, Pyrhonen SO. Phase II trial of oral carmofur in advanced pancreatic carcinoma. Ann Oncol 1991;2:765-6.
7. Moore DF Jr., Pazdur R, Abbruzzese JL, Ajani JA, Dubovsky DW, Wade JL III, et al. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1994;5:286-7.
8. Casper ES, Schwartz GK, Johnson B, Kelsen DP. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 1992;10:313-6.
9. Casper ES, Schwartz GK, Kelsen DP. Phase II trail of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 1992;10:205-9.
10. Rosvold E, Schilder R, Walczak J, DiFino SM, Flynn RJ, Banerjee TK, et al. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. Cancer Chemother Pharmacol 1992;29:305-8.
11. Morrell LM, Ardalan B, Richman SP, Goodman P, Fleming TR, MacDonald JS. A phase II multi-institutional trial of low-dose n-(phosphonacetyl)-1-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas: a Southwest Oncology Group study. Cancer 1991;67:363-6.
12. Kilton LJ, Benson AB III, Greenberg A, Johnson P, Shapiro C, Blough R, et al. Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas: an Illinois Cancer Centre study. Invest New Drugs 1992;10:201-4.
13. Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994;12:29-34.
14. Philip PA, Carmichael J, Tonkin K, Buamah PK, Britton J, Dowsett M, et al. Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone. Br J Cancer 1993;67:379-82.
15. Allegretti A, Lionetto R, Saccomanno S, Paganuzzi M, Onetti M, Martinali C, et al. OH-RH analogue treatment in adenocarcinoma of the pancreas: a phase II study. Oncology 1993;50:77-80.
16. Hubbard KP, Pazdur R, Ajani JA, Broud E, Blaustein A, King M, et al. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol (CCT) 1992;15:524-7.
17. Brown TD, Goodman PJ, Fleming TR, Baker LH, MacDonald JS. Phase II trial of menogarril in adenocarcinoma of the pancreas: a Southwest Oncology Group study. Invest New Drugs 1991;9:77-8.
18. Kraut EH, Fleming T, MacDonald JS, Spiridonidis CH, Bradof JE, Baker LH. Phase II trial of merbarone in pancreatic carcinoma: a Southwest Oncology Group Study. Am J Clin Oncol 1993;16:327-8.
19. Jones DV Jr, Ajani JA, Winn RJ, Daugherty KR, Lavin BR, Krakoff IH. A phase II study of merbarone in patients with adenocarcinoma of the pancreas. Cancer Invest 1993; 11:667-9.
20. Abbruzzese JL, Gholson CF, Daugherty K, Larison E, DuBrow R, Berlin R, et al. A pilot clinical trial of the cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. Pancreas 1992;7:165-71.
21. Weiner LM, Harvey E, Padavic-Shaller K, Willson JKV, Walsh C, LaCreta F, et al. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic carcinoma. J Immunother 1993;13:110-6.
22. Friess H, Buchler M, Beglinger C, Weber A, Kunz J, Fritsch K, et al. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993; 8:540-5.
23. Kraut EH, Fleming TR, Segal M, Neidhart JA, Behrans BC, MacDonald JS. Phase II study of pibenzimol in pancreatic cancer: a Southwest Oncology Group study. Invest New Drugs 1991;9:95-6.
24. Patel SR, Kvols LK, Rubin J, O'Connell MJ, Edmonson JH, Ames MM, et al. Phase I-II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma. Invest New Drugs 1991;9:53-7.
25. Jenkins TR, Tangen C, MacDonald JS, Weiss GR, Chapman R, Hertel A. A phase II trial of piroxantrone in adenocarcinoma of the pancreas: a Southwest Oncology Group study. Invest New Drugs 1993;11:329-31.
26. Conobbio L, Boccardo F, Cannata D, Gallotti P, Epis R. Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Cancer 1992;69:648-50.
27. Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Belt R. Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. Invest New Drugs 1991;9:369-71.
28. Brown TD, Goodman P, Fleming T, MacDonald JS, Hersh EM, Braun TJ. A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study. J Immunother 1991; 10:376-8.
29. Taylor I. Should further studies of chemotherapy be carried out in pancreatic cancer? Eur J Cancer 1993;29A:1076-8.
30. Howard JM, Jordan GL Cancer of the pancreas. Curr Probl Cancer 1977;2:1-35.
31. Greenwald HP, Bonica JJ, Bergner M. The prevalence of pain in four cancers. Cancer 1987;60:2563-9.
32. Perez MM, Newcomer AD, Moertel CG, Go VLW, Dimagno EP. Assessment of weight loss, food intake, fat metabolism, malabsorption, and treatment of pancreatic insufficiency in pancreatic cancer. Cancer 1983;52:346-52.
33. Flanigan D, Kraft R. Continuing experience with palliative chemical splanchnicectomy. Arch Surg 1978;113:509-14.
34. O'Shaughnessy JA, Wittes RE, Burke G, Friedman MA, Johnson JR, Neiderhuber JE, et al. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J Clin Oncol 1991;9:2225-32.
35. Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric cancer. JAMA 1985;253:2061-7.
36. Fishman B, Pasternak S, Wallenstein SL, Houde RW, Holland JC, Foley KM. The Memorial Pain Assessment Card: a valid instrument for the evaluation of cancer pain. Cancer 1987;60:1151-8.
37. Daut RL, Cleeland CS, Flannery RC. The development of the Wisconsin Brief Pain Questionnaire to assess pain in cancer and other diseases. Pain 1983;17:197-210.
38. Rothenberg ML, Burris HA III, Andersen JS, Moore M, Green MR, Portenoy RK, et al. Gemcitabine: effective palliative therapy for pancreas cancer patients failing 5-FU [abstract 470]. Proc Am Soc Clin Oncol 14:198.
39. Karnofsky DA, Abelmann WH, Craver LF, Burchenal JH. The use of the nitrogen mustards in the palliative treatment of carcinoma. Cancer 1948;1:634-56.
40. Koretz RL. Parenteral nutrition: is it oncologically logical? J Clin Oncol 1984;2:534-5.
41. Schipper H, Clinch J, McMurray A, Levitt M. Measuring the quality of life of cancer patients: the functional living index-cancer. Development and validation. J Clin Oncol 1984; 2:472-83.
42. Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The Functional Assessment of Cancer Therapy Scale: development and validation of the general measure. J Clin Oncol 1993;11:570-9.
43. Ganz PA, Schag CAC, Lee JJ, Simm S. The CARES: a generic measure of health-related quality of life for patients with cancer. Qual Life Res 1992;1:19-29.
44. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLC-C30: a quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365-76.
45. Moinpour CM, Feigl P, Metch B, Hayden KA, Meyskens FL Jr, Crowley J. Quality of life endpoints in cancer clinical trials: review and recommendations. J Natl Cancer Inst 1989;81:485-95.
46. Gotay CC, Korn EL, McCabe MS, Moore TD, Cheson BD. Quality of life assessment in cancer treatment protocol: research issues in protocol development. J Natl Cancer Inst 1992;84:575-9.
47. Moore M, Andersen J, Burris H, Tarassoff P, Green M, Casper E, et al. A randomized trial of gemcitabine versus 5-FU as first-line therapy in advanced pancreatic cancer [abstract 473]. Proc Am Soc Clin Oncol 1995;14:199.
48. Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA III, et al. A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 1996;7:347-53.